{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:20:22Z","timestamp":1778545222720,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011249","name":"Robert H. Lurie Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011249","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.nano.2020.102290","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T11:59:41Z","timestamp":1597319981000},"page":"102290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Adam Yuh","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan Scott","family":"Rink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masha","family":"Kocherginsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colby Shad","family":"Thaxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo I","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.nano.2020.102290_bb0005","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2017-04-737320","article-title":"How I treat double-hit lymphoma","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"issue":"38","key":"10.1016\/j.nano.2020.102290_bb0010","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/EDBK_200549","article-title":"Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma","author":"Strati","year":"2018","journal-title":"Am Soc Clin Oncol Educ book Am Soc Clin Oncol Annu Meet"},{"issue":"2","key":"10.1016\/j.nano.2020.102290_bb0015","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/vaccines3020390","article-title":"CpG Oligonucleotides as Cancer Vaccine Adjuvants","volume":"3","author":"Shirota","year":"2015","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.nano.2020.102290_bb0020","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.4049\/jimmunol.169.7.3892","article-title":"Peritumoral CpG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors to Cure Established Tumors in a Murine Colon Carcinoma Model","volume":"169","author":"Heckelsmiller","year":"2002","journal-title":"J Immunol"},{"issue":"24","key":"10.1016\/j.nano.2020.102290_bb0025","doi-asserted-by":"crossref","first-page":"11980","DOI":"10.1158\/0008-5472.CAN-07-1526","article-title":"Activation of tumor-specific CD8+ T cells after intratumoral Ad5-TRAIL\/CpG oligodeoxynucleotide combination therapy","volume":"67","author":"VanOosten","year":"2007","journal-title":"Cancer Res"},{"issue":"46","key":"10.1016\/j.nano.2020.102290_bb0030","doi-asserted-by":"crossref","first-page":"E7240","DOI":"10.1073\/pnas.1608555113","article-title":"Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells","volume":"113","author":"Wang","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.nano.2020.102290_bb0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12967-017-1152-5","article-title":"Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application","volume":"15","author":"Bai","year":"2017","journal-title":"J Transl Med"},{"issue":"3\u20134","key":"10.1016\/j.nano.2020.102290_bb0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.molimm.2013.01.001","article-title":"CpG oligodeoxynucleotide induces apoptosis and cell cycle arrest in A20 lymphoma cells via TLR9-mediated pathways","volume":"54","author":"Qi","year":"2013","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.nano.2020.102290_bb0045","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/cmi.2013.14","article-title":"Toll-like receptor agonists induce apoptosis in mouse B-cell lymphoma cells by altering NF-\u03baB activation","volume":"10","author":"Arunkumar","year":"2013","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/j.nano.2020.102290_bb0050","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.4049\/jimmunol.1101304","article-title":"Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells","volume":"188","author":"Shirota","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.nano.2020.102290_bb0055","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-18-0743","article-title":"In Situ Vaccination with a TLR 9 Agonist and Local Low Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma","author":"Frank","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.nano.2020.102290_bb0060","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/smll.201402179","article-title":"In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models","volume":"11","author":"Almeida","year":"2015","journal-title":"Small"},{"issue":"5","key":"10.1016\/j.nano.2020.102290_bb0065","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.4049\/jimmunol.181.5.2990","article-title":"Targeting CpG Oligonucleotides to the Lymph Node by Nanoparticles Elicits Efficient Antitumoral Immunity","volume":"181","author":"Bourquin","year":"2008","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.nano.2020.102290_bb0070","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/adfm.201302347","article-title":"Engineered CpG-Antigen Conjugates Protected Gold Nanoclusters as Smart Self-Vaccines for Enhanced Immune Response and Cell Imaging","volume":"24","author":"Tao","year":"2014","journal-title":"Adv Funct Mater"},{"issue":"5","key":"10.1016\/j.nano.2020.102290_bb0075","doi-asserted-by":"crossref","first-page":"e63550","DOI":"10.1371\/journal.pone.0063550","article-title":"Gold Nanoparticle Delivery of Modified CpG Stimulates Macrophages and Inhibits Tumor Growth for Enhanced Immunotherapy","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"issue":"49","key":"10.1016\/j.nano.2020.102290_bb0080","doi-asserted-by":"crossref","first-page":"19902","DOI":"10.1073\/pnas.1313152110","article-title":"Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose","volume":"110","author":"De Titta","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.nano.2020.102290_bb0085","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1021\/ja808719p","article-title":"Gene regulation with polyvalent siRNA-nanoparticle conjugates","volume":"131","author":"Giljohann","year":"2009","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.nano.2020.102290_bb0090","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/1556-276X-6-283","article-title":"T cells enhance gold nanoparticle delivery to tumors in vivo","volume":"6","author":"Kennedy","year":"2011","journal-title":"Nanoscale Res Lett"},{"issue":"2","key":"10.1016\/j.nano.2020.102290_bb0095","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF02678536","article-title":"Augumentation of splenic antitumor immunity by local immunotherapy in gastric cancer patients","volume":"10","author":"Wakasugi","year":"1997","journal-title":"Biotherapy"},{"issue":"33","key":"10.1016\/j.nano.2020.102290_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau6085","article-title":"Structure and function of the immune system in the spleen","volume":"4","author":"Lewis","year":"2019","journal-title":"Sci Immunol"},{"issue":"4","key":"10.1016\/j.nano.2020.102290_bb0105","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/smll.201301998","article-title":"In vivo immune cell distribution of gold nanoparticles in Na??ve and tumor bearing mice","volume":"10","author":"Almeida","year":"2014","journal-title":"Small"},{"issue":"3","key":"10.1016\/j.nano.2020.102290_bb0110","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ymthe.2017.12.018","article-title":"The Effect of Size and Shape of RNA Nanoparticles on Biodistribution","volume":"26","author":"Jasinski","year":"2018","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.nano.2020.102290_bb0115","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ajh.23460","article-title":"A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma","volume":"88","author":"Witzig","year":"2013","journal-title":"Am J Hematol"},{"issue":"426","key":"10.1016\/j.nano.2020.102290_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4488","article-title":"Eradication of spontaneous malignancy by local immunotherapy","volume":"10","author":"Sagiv-Barfi","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nano.2020.102290_bb0125","series-title":"Immunotherapy of Cancer: An Innovative Treatment Comes of Age","article-title":"Overview of current cancer immunotherapy","volume":"228","author":"Yamaguchi","year":"2016"},{"issue":"1","key":"10.1016\/j.nano.2020.102290_bb0130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/eji.200324032","article-title":"Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities","volume":"34","author":"Vollmer","year":"2004","journal-title":"Eur J Immunol"},{"issue":"32","key":"10.1016\/j.nano.2020.102290_bb0135","doi-asserted-by":"crossref","first-page":"15700","DOI":"10.1021\/jp061667w","article-title":"Turkevich Method for Gold Nanoparticle Synthesis Revisited","volume":"110","author":"Kimling","year":"2006","journal-title":"J Phys Chem B"},{"issue":"48","key":"10.1016\/j.nano.2020.102290_bb0140","doi-asserted-by":"crossref","first-page":"13600","DOI":"10.1073\/pnas.1610028113","article-title":"Controlling DNA\u2013nanoparticle serum interactions","volume":"113","author":"Zagorovsky","year":"2016","journal-title":"Proc Natl Acad Sci"},{"issue":"15_suppl","key":"10.1016\/j.nano.2020.102290_bb0145","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1200\/jco.2010.28.15_suppl.8076","article-title":"Effect of CpG oligodeoxynucleotides on the growth of aggressive human B-cell lymphomas","volume":"28","author":"Yamada","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.nano.2020.102290_bb0150","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1158\/1078-0432.CCR-04-1890","article-title":"B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides","volume":"11","author":"Jahrsdorfer","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.nano.2020.102290_bb0155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hon.2251","article-title":"Concomitant high expression of toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma","volume":"35","author":"Akhter","year":"2017","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.nano.2020.102290_bb0160","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/(SICI)1521-4141(199904)29:04<1209::AID-IMMU1209>3.0.CO;2-J","article-title":"CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells","volume":"29","author":"Bendigs","year":"1999","journal-title":"Eur J Immunol"},{"issue":"10","key":"10.1016\/j.nano.2020.102290_bb0165","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.nano.2020.102290_bb0170","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.nano.2020.102290_bb0175","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/0008-5472.CAN-18-0729","article-title":"Inhaled tlr9 agonist renders lung tumors permissive to pd-1 blockade by promoting optimal CD4\u00fe and CD8\u00fe T-cell Interplay","volume":"78","author":"Gallotta","year":"2018","journal-title":"Cancer Res"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963420301441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963420301441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:11:52Z","timestamp":1761549112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963420301441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":35,"alternative-id":["S1549963420301441"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2020.102290","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2020.102290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102290"}}